Stella Hahn

ORCID: 0000-0002-9110-6518
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Respiratory Support and Mechanisms
  • Sepsis Diagnosis and Treatment
  • Obstructive Sleep Apnea Research
  • Pleural and Pulmonary Diseases
  • Clinical Reasoning and Diagnostic Skills
  • Ultrasound in Clinical Applications
  • Reliability and Agreement in Measurement
  • Sleep and Wakefulness Research
  • COVID-19 Clinical Research Studies
  • Long-Term Effects of COVID-19
  • EEG and Brain-Computer Interfaces
  • Sleep and related disorders
  • Psychosomatic Disorders and Their Treatments
  • Dysphagia Assessment and Management
  • Infective Endocarditis Diagnosis and Management
  • Meta-analysis and systematic reviews
  • Neonatal and Maternal Infections
  • Pulmonary Hypertension Research and Treatments
  • Amoebic Infections and Treatments
  • Eating Disorders and Behaviors
  • Restless Legs Syndrome Research
  • Thyroid Cancer Diagnosis and Treatment
  • Frailty in Older Adults
  • Transplantation: Methods and Outcomes
  • Actinomycetales infections and treatment

Northwell Health
2016-2024

University of Kansas Medical Center
2022

Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
2018-2022

Jersey Shore University Medical Center
2022

Catholic Health Initiatives
2022

Feinstein Institute for Medical Research
2022

Hofstra University
2015-2021

Long Island Jewish Medical Center
2020

North Shore University Hospital
2020

Penn State Milton S. Hershey Medical Center
2020

Rationale: A molecular test to distinguish between sepsis and systemic inflammation of noninfectious etiology could potentially have clinical utility.Objectives: This study evaluated the diagnostic performance a host response assay (SeptiCyte LAB) designed in critically ill adults.Methods: The employed prospective, observational, noninterventional design recruited heterogeneous cohort adult critical care patients from seven sites United States (n = 249). An additional group 198 patients,...

10.1164/rccm.201712-2472oc article EN American Journal of Respiratory and Critical Care Medicine 2018-04-06

Differentiating sepsis from the systemic inflammatory response syndrome (SIRS) in critical care patients is challenging, especially before serious organ damage evident, and with variable clinical presentations of training experience attending physicians. Our objective was to describe quantify physician agreement diagnosing SIRS or as a function available information, infection site, hospital setting. We conducted post hoc analysis previously collected data prospective, observational trial (N...

10.1186/s40560-019-0368-2 article EN cc-by Journal of Intensive Care 2019-02-20

As we are over a year into the COVID-19 pandemic, have made many forward strides in therapeutics. These treatments, such as monoclonal antibodies, help mitigate detrimental and often fatal consequences of COVID-19. The current indication for use antibodies is mild to moderate infection within 10 days symptom onset those who at high risk progression severe disease. However, their role patients with prolonged symptoms not clear. We present unique case after 54 an immunosuppressed patient...

10.1136/bcr-2021-243469 article EN BMJ Case Reports 2021-08-01

Objective The study aims to describe the clinical characteristics and outcomes of patients with COVID-19 related acute respiratory distress syndrome (ARDS) who developed pneumothorax. Design setting A retrospective chart review was performed electronic medical record. Patients were included if they identified as having confirmed well pneumothorax from March 16, 2020 May 31, 2020. Patients' demographic characteristics, mechanical ventilator parameters, lung compliance measurements during...

10.7759/cureus.11749 article EN Cureus 2020-11-28

Introduction Treatment with dexamethasone reduces mortality in patients coronavirus disease 2019 (COVID-19) pneumonia requiring supplemental oxygen, but the optimal dose has not been determined. Objective To determine whether weight-based of 0.2 mg/kg is superior to 6 mg daily reducing 28-day COVID-19 and hypoxemia. Materials methods A multicenter, open-label, randomized clinical trial was conducted between March 2021 December at seven hospitals within Northwell Health. total 142 confirmed...

10.7759/cureus.31086 article EN Cureus 2022-11-04

Prior studies concentrated on unplanned intensive care unit (ICU) transfer to gauge deterioration occurring shortly following hospital admission. However, examining only ICU transfers is not ideal since patients could stabilize with treatment, refuse admission, or require evaluation. To further explore etiologies of early clinical deterioration, we used rapid response team (RRT) activation within 48 hours admission as an index worsening.A retrospective analysis prospectively gathered...

10.2147/ijgm.s145933 article EN cc-by-nc International Journal of General Medicine 2017-09-01

The mainstay of treatment for obstructive sleep apnea is positive airway pressure therapy, which may be difficult some patients to tolerate leading compromised adherence and requiring alternative therapies.Hypoglossal nerve stimulation has become an option those who meet implantation criteria.Implantation the device ambulatory surgical procedure generally well-tolerated, though rare adverse events have been reported.We report unusual complication hypoglossal in a patient had initial success...

10.5664/jcsm.9492 article EN Journal of Clinical Sleep Medicine 2021-06-23

Abstract Introduction Obstructive sleep apnea (OSA) has significant physiologic consequences. The Apnea-Hypopnea Index (AHI) is used to define severity, but AHI only reflects the rate of sleep-disordered breathing events and does not correlate well with clinical outcomes that arise from hypoxia. Percentage cumulative time oxygen saturation below 90% (T90) hypoxic burden (HBI) more accurately reflect nocturnal hypoxia may be suitable correlates morbidity associated apnea. Rising Red Cell...

10.1093/sleep/zsae067.0499 article EN SLEEP 2024-04-20

Abstract Introduction HGNS is an approved therapy for obstructive sleep apnea (OSA). Initial setting of voltage based on observation anterior tongue movement, which may not reflect opening the retroglossal airway. We developed ultrasonographic (US) technique to assess movement with HGNS. correlated US measures at initial AHI determined by PSG/HSAT therapy. Methods Eleven subjects implanted INSPIRE™ (HGNS) were enrolled least one month post-implantation. was while awake and semi-recumbent set...

10.1093/sleep/zsaa056.645 article EN SLEEP 2020-04-01

10.1007/s13665-017-0184-x article EN Current Pulmonology Reports 2017-06-09

Graves' disease may go along with the occurrence of lymphoid-like clusters within thyroid. However, information about their specific importance and intrathyroidal upregulation molecules in network maturation antigen-presenting cells like dendritic (DC) is scarce. We here studied by immunohistochemistry thyroid cryostat sections patients Graves (GD) (n=25), for control toxic goiter (TG) (n=18) non-toxic (NG) (n=16). In all entities, immature (MHC class II+CD40-CD80-) were tightly associated...

10.1055/s-2004-819240 article EN Experimental and Clinical Endocrinology & Diabetes 2004-03-02

Abstract Introduction New sensor technologies are entering sleep testing at a rapid pace; Neteera™ developed novel and algorithm for apnea detection utilizing contact-free, radar-based system. The system utilizes high-frequency, low-power, directional micro-radar which operates ~120GHz sampling rate of 2500Hz as well algorithms able to detect both pulse respiratory activity subjects during sleep. Methods Adult undergoing diagnostic PSG clinical purposes were simultaneously assessed with the...

10.1093/sleep/zsaa056.581 article EN SLEEP 2020-04-01

Narcolepsy is a lifelong disorder that adversely affects daytime function and quality of life. Major symptoms include excessive sleepiness with irrepressible sleep attacks cataplexy. Recent developments in the understanding pathobiology narcolepsy, as well neuronal systems involved regulation wakefulness have led to development new pharmacologic approaches therapy. In this paper, we review available treatments for narcolepsy agents currently under investigation.

10.17925/usn.2022.18.1.68 article EN cc-by-nc touchREVIEWS in Neurology 2022-01-01
Coming Soon ...